Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Macular Degeneration
Interventions
DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals

DRUG

Anecortave Acetate Sterile Suspension, 60 mg/mL

One 0.5 mL posterior juxtascleral depot injection at 6 month intervals

OTHER

Anecortave Acetate Vehicle

One 0.5 mL sham injection at 6 month intervals

Trial Locations (1)

76134

Alcon Study Sites, Fort Worth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alcon Research

INDUSTRY